Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1,155 MXN
Change Today 0.00 / 0.00%
Volume 0.0
TEVAN On Other Exchanges
Symbol
Exchange
New York
OTC US
Tel Aviv
As of 4:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVAN) Snapshot

Open
$1,150
Previous Close
$1,155
Day High
$1,155
Day Low
$1,150
52 Week High
07/28/15 - $1,155
52 Week Low
09/9/14 - $677.00
Market Cap
981.8B
Average Volume 10 Days
914.3
EPS TTM
--
Shares Outstanding
850.0M
EX-Date
08/18/15
P/E TM
--
Dividend
$1.35
Dividend Yield
1.65%
Current Stock Chart for TEVA PHARMACEUTICAL-SP ADR (TEVAN)

teva pharmaceutical-sp adr (TEVAN) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil and Provigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora/Effentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Zecuity for the treatment of migraine in adults; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. This segment’s products in the respiratory market include ProAir, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Trisenox, Granix, Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, and Eporatio products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and Zoely. In addition, the company provides branded over-the-counter medicines in the categories of cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications; and sells third-party products, such as medical devices and other miscellaneous items. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Petach Tikva, Israel.

43,009 Employees
Last Reported Date: 02/9/15
Founded in 1901

teva pharmaceutical-sp adr (TEVAN) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $3.3M
Compensation as of Fiscal Year 2014.

teva pharmaceutical-sp adr (TEVAN) Key Developments

Rigrodsky & Long Announces Securities Fraud Class Action Lawsuit Against Teva Pharmaceutical Industries Limited

Rigrodsky & Long, P. A announced that a complaint was filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the securities of Teva Pharmaceutical Industries Limited between August 1, 2013 and October 29, 2013, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against certain of the Company’s officers. The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business operations, financial condition and prospects. Specifically, the Complaint alleges that the defendants failed to disclose that there was significant internal discord between the Board of Directors (“Board”) and Teva’s senior management during the Class Period (and in particular, significant differences between the Chairman of the Board and the Chief Executive Officer (“CEO”)) concerning execution of the Company’s strategies, including implementation of the critical Cost Cutting Program. As aresult of the foregoing, the Company’s stock traded at artificially inflated prices during the Class Period.

Teva Arranges USD 33.75 Billion in Financing for Allergan Generics Purchase

Teva Pharmaceutical Industries Ltd. has secured financing commitments for USD 33.75 billion to cover the cash portion of its deal for the Allergan Plc. Teva said the money will come from a banking syndicate comprising Bank of America Merrill Lynch, Barclays Bank Plc, BNP Paribas SA, Citigroup Inc, Credit Suisse Group AG, HSBC Holdings Plc, Mizuho Bank, Morgan Stanley Senior Funding Inc, RBC Capital Markets and Sumitomo Mitsui Banking Corporation. Under the terms of the commitment letters, the banks will provide Teva with up to USD 27 billion under a senior unsecured bridge loan credit facility and up to USD 6.75 billion under an equity bridge loan credit facility. Among the standard conditions attached to the commitments is entry into definitive financing agreements. Under the terms of the definitive agreement, Teva will pay USD 33.75 billion in cash for Allergan Generics and submit USD 6.75 billion in shares, giving Allergan a Teva stake of close to 10%. Teva group said at the time it expected to secure financing commitments within 15 business days, with Allergan having the right to walk away from the deal if these commitments are not obtained. The transaction has the full support of Teva's and Allergan's boards and is seen as closing during the first quarter of 2016.

Teva Looking To acquire Sandoz

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is considered acquiring Sandoz International GmbH from Novartis AG (SWX:NOVN).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVAN:MM $1,155.00 MXN 0.00

TEVAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.51 USD +0.01
AbbVie Inc $69.95 USD +0.22
AstraZeneca PLC 4,385 GBp +43.00
Eli Lilly & Co $84.05 USD -0.09
Medtronic PLC $77.77 USD -0.23
View Industry Companies
 

Industry Analysis

TEVAN

Industry Average

Valuation TEVAN Industry Range
Price/Earnings 23.6x
Price/Sales 2.9x
Price/Book 2.6x
Price/Cash Flow 26.4x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.